Pentraxins as key disease markers for periodontal diagnosis

Disease Markers

Volumn 34, Issue 3, 2013, Pages 143-151

  Kathariya, Rahul ^a   Jain, Hansa ^a   Gujar, Dnyneshwari ^a   Singh, Archana ^a   Ajwani, Himanshu ^a   Mandhyan, Devendra ^b  

^a DR D Y PATIL DENTAL COLLEGE AND HOSPITAL   (India)

^b Chandra Dental College   (India)

Author keywords

biomarkers; C reactive protein; pentraxin 3; Pentraxins; periodontal disease

Indexed keywords

ACUTE PHASE PROTEIN; AMYLOID PROTEIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CARRIER PROTEIN; COMPLEMENT; PENTRAXIN; PENTRAXIN 3; PROTEINASE;

ACUTE PHASE RESPONSE; CHRONIC DISEASE; CHRONIC PERIODONTITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; GINGIVITIS; HUMAN; INNATE IMMUNITY; PERIODONTAL DISEASE; PERIODONTAL EXAMINATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; SOFT TISSUE INFLAMMATION;

EID: 84874391096     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/259273     Document Type: Review

References (81)

1. Slots J. Subgingival microflora and periodontal disease. J Clin Periodontol 1979; 6: 351-352.
2. Takeichi O, Haber J, Kawai T. Cytokines profiles of T lymphocytes from gingival tissues with pathological pocket. J Dent Res 2000; 79: 1548-55.
3. Offenbacher S. Periodontal disease: pathogenesis. Ann Periodontol 1996; 1: 821-878.
4. Ebersole, Capell D. Acute-phase reactants in infection and inflammatory diseases. Periodontol 2000 2000; 23: 19-49.
5. Armitage GC. The complete periodontal examination. Periodontol 2000. 2004; 34: 22-33.
6. Hafajee AD, Socransky SS, Goodson JM. Clinical parameters as predictors of destructive periodontal activity, J Clin Periodontol 1983; 10: 257.
7. Sanz M, Newman MG, Quirynen M. Advanced diagnostic techniques. In: Carranza's Clinical periodontology, 10th ed Noida: Elsevier Saunders press, 2006; 579.
8. Lang NP, Tonetti MS. Periodontal diagnosis in treated periodontitis. Why, when and how to use clinical parameters. J Clin Periodontol 1996; 23: 240-250.
9. Taber's online [homepage on the internet] Taber's Cyclopedic Medical Dictionary, 21st Edition [updated 23 Jun 2009; cited 13 Mar 2011]. Available from: http://www.tabers. com/tabersonline/ub/view/Tabers/143851/27/acute-phase- protein?q=acutr%20phase%20reactants.
10. Stashenko P, Obernesser MS, Prostak L, Haffajee AD, Socransky S. Levels of interlukin 1β in tissue sites of active periodontal disease. J Clin Periodontol 1991; 18: 548-554.
11. Mosmann TR, Coffman R. Th1 and Th2 cells: different pattern of lymphokine production lead to different functional properties. Annu Rev Immunol 1989; 7: 145-173.
12. Gemmell E, Marshall RI, Seymour GJ. Cytokines and prostaglandins in immune homeostasis and tissue destruction in periodontal disease. Periodontal 2000 1997; 14: 112-143.
13. Martinez de, la Torre Y, Fabbri M, Jaillon S, Bastone A, Nebuloni M, Vecchi A, Mantovani A, Garlanda C. Evolution of the pentraxin family: The new entry PTX4. J Immunol 2010; 184(9): 5055-64.
14. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-366.
15. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immuol Today 1994; 15: 81-87.
16. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factorand IL-1-inducible protein, is a novel member of the pentraxin family of acute phase proteins. J Immunol 1993; 150: 1804-1812.
17. Reid MS, Blobel CP. Apexin, an acrosomal pentraxin. J Biol Chem. 1994; 269(51): 32615-20.
18. Moalli F, Jaillon S, Inforzato A, Sironi M, Bottazzi B, Mantovani A, et al. Pathogen recognition by the long pentraxin PTX3. J Biomed Biotechnol 2011; 2011: 830421.
19. Gabay C, Kusher I. Acute-Phase Proteins and Other Systemic Responses to Inflammation. N Engl J Med 1999; 340: 448-54. [PubMed: 9971870].
20. Slade GD, Ghezzi EM, Heiss G, Beck JD, Riche E, Offenbacher S. Relationship Between Periodontal Disease and CReactive Protein Among Adults in the Atherosclerosis Risk in Communities Study. Arch Intern Med 2003; 163: 1172-9. [PubMed: 12767953].
21. Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S. Periodontal Disease and Cardio Vascular Disease. J Periodontol 1996; 67(10 Suppl): 1123-37. [PubMed: 8910831].
22. Kanaparthy A, Kanaparthy R, Niranjan N. Evaluation of serum C-reactive protein levels in subjects with aggressive and chronic periodontitis and comparison with healthy controls. Dent Res J 2012; 9(3): 261-265.
23. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
24. James Beck, Steven Offenbacher Relationship among clinical measures of periodontal disease and their associations with systemic markers. Ann Periodontol 2002; 7: 79-89.
25. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl JMed 1997; 336: 973-9.
26. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
27. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
28. Ridker PM, Glynn RJ, Hennekens CH. C-Reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-11.
29. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, et al. Increased C-reactive protein levels in the polycystic ovary syndrome a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89(5): 2160-5.
30. Johnson NW, Griffiths GS, Wilton JM, et al. Detection of high-risk groups and individuals for periodontal disease. Evidence for the existence of higher groups and individuals and approaches to their detection. J Clin Periodontol 1998; 15: 276-82.
31. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol 2001; 72: 1221-7.
32. Slade GD, Offenbacher S, Beck JD, et al. AP inflammatory response to periodontal disease in the US population. J Dent Res 2000; 79: 49-57.
33. Bruno G. Loos. Systemic markers of inflammation in periodontitis. J Periodontol 2005; 76: 2106-15.
34. US National Library of Medicine. National Library of Medicine. 2011. C reactive protein and periodontal disease URL: http://www.ncbi.nlm.nih.gov/ pubmed?term=c%20reac tive%20protein%20in%20periodontal%20disease.
35. Gewurz H, Mold C, Siegal J, Fiedel B. C-reactive protein and APP response. Adv Intern Med 1982; 27: 345-72.
36. Fitzsimmons TR, Sanders AE, Bartold PM, Slade GD. Local and systemic biomarkers in gingival crevicular fluid increase odds of periodontitis. J Clin Periodontol 2010; 37(1): 30-6.
37. AR Pradeep, RGS Manjunath and Kathariya R. Progressive periodontal disease has a simultaneous incremental elevation of gingival crevicular fluid and serum CRP levels. JICD 2010; 1: 133-138.
38. Tuter G, Kurtis B, Serdar M. Evaluation of gingival crevicular fluid and serum levels of high-sensitivity C-reactive protein in chronic periodontitis patients with or without coronary artery disease. J Periodontol 2007; 78: 2319-24.
39. Kathariya A, Dyneshwari G, Bokil S. Association of CRP and periodontal inflammatory burden in periodontitis patients and effect of periodontal therapy on its modulation. (Unpublished data).
40. Marcaccini AM, Meschiari AC, Sorgi CA, et al. Circulating interleukin-6 and high-sensitivity C-reactive protein decrease after periodontal therapy in otherwise healthy subjects. J Periodontol 2009; 80: 594-602.
41. Tripepi G,Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 16(1): S83-S88.
42. Cathcart ES, Shirahama T, Cohen AS. Isolation and identification of a plasma component of amyloid. Biochim Biophy Acta 1967; 147: 392-393.
43. Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci 1995 92(10): 4299-303.
44. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: A prominent acute-phase reactant for clinical practice. Eur J Clin Investig 1996; 26: 427-435.
45. Skinner M, Vaitukaitis JL, Cohen AS, Benson MD. Serum amyloid P-component levels in amyloidosis, connective tissue diseases, infection, and malignancy as compared to normal serum. J Lab Clin Med 1979; 94(4): 633-638.
46. Short LL, Zoellner H, Hunter N. Association of amyloid P protein with pathology in periodontal tissues. J Oral Pathol Med 1994; 23(8): 354-7.
47. Short LL, Zoellner H, Hunter N. Extraction of amyloid-like fibrils from chronically inflamed periodontal tissues. J Oral Pathol Med 1994; 23(8): 358-63.
48. Behle JH, Sedaghatfar MH, Demmer RT, et al. Heterogeneity of systemic inflammatory responses to periodontal therapy. J Clin Periodontol 2009; 36(4): 287-94.
49. ChoWC, Yip TT, Yip C, Yip V, Thulasiraman V, Ngan RK, et al. Identification of Serum Amyloid A protein as potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004; 10: 43-52.
50. Sumitsawan Y, Chaiyasate S, Chitapanarux I, Anansuthiwara M, Roongrotwattanasiri K, Vaseenon V, et al. Late complications of radiotherapy for nasopharyngeal carcinoma. Auris Nasus Larynx 2009; 36(2): 205-9.
51. Bozinovski S, Hutchinson A, Thompson M, Macgregor L, Black J, Giannakis E, et al. Serum Amyloid A Is a Biomarker of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2008; 177(3): 269-78.
52. Deo V, Bhongade ML, Ansari S, Chavan RS. Periodontitis as a potential risk factor for chronic obstructive pulmonary disease: A retrospective study. Indian J Dent Res 2009; 20(4): 466-70.
53. Okutani D. The role of long pentraxin 3, a new inflammatory mediator in inflammatory responses. Nihon Rinsho Meneki Gakkai Kaishi 2006; 29:3: 107-113.
54. Fazzini F, Peri G, Doni A, Dell'Antonio G, Dal Cin E, Bozzolo E. et al. PTX3 in small-vessel vasculitides: An independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001; 44: 2841-2850.
55. Johnson NW, Griffiths GS, Wilton JM, et al. Detection of high-risk groups and individuals for periodontal disease. Evidence for the existence of higher groups and individuals and approaches to their detection. J Clin Periodontol 1998; 15: 276-82.
56. Pradeep AR, Kathariya R, Raghavendra NM, Sharma A. Levels of Pentraxin-3 in Gingival Crevicular Fluid and Plasma in Periodontal Health and Disease. J Periodontology 2011; 82(5): 734-41.
57. Pradeep AR, Kathariya R, Sushmarani R, Sharma A, Raghavendra NM. Risk factors for chronic kidney diseases may include periodontal disease: As estimated by the correlations of plasma pentraxin 3 levels: A case control study. Int Urol Nephrol 2012; 44(3): 829-39.
58. Savchenko A, Imamura M, Ohashi R, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008; 215: 48-55.
59. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007; 27: 161-167.
60. Peri G, Introna M, Corradi D, et al. PTX3. A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102: 636-641.
61. Giuseppe A, Ramirez, Stefano Franchini, Patrizia Rovere-Querini, Maria Grazia Sabbadini, Angelo A. Manfredi, Norma Maugeri. The role of platelets in the pathogenesis of systemic sclerosis. Front Immunol 2012; 3: 160.
62. Reading PC, Bozza S, Gilbertson B, et al. Antiviral activity of the long chain pentraxin PTX3 against Influenza Viruses. J Immunol 2008; 180: 3391-3398.
63. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349-2354.
64. Tong M, Correro JJ, Qureshi AR, et al. Plasma Pentraxin 3 in Patients with Chronic Kidney Disease: Associations with Renal Function, Protein-Energy Wasting, Cardiovascular Disease, and Mortality. Clin J Am Soc Nephrol 2007; 2: 889-897.
65. Luchetti MM, Piccinini G, Mantovani A, et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 119: 196-202.
66. Cetin I, Cozzi V, Pasqualini F, et al. Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2006; 194: 1347-1353.
67. Shingo K, Mitsuko O, Tomaya S, et al. Increased expression of long pentraxin in inflammatory bowel diseases. Dig Dis Sci 2008; 53: 1910-1916.
68. Albert TAM, Giuseppe P, Tatty ES, et al. Elevated plasma levels of the long pentraxin, Pentraxin 3 in severe dengue virus infections. J Medical Virol 2005; 76: 547-552.
69. Diamandis EP, Goodglick L, Planque C, Thornquist MD. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res 2011; 17(8): 2395-9.
70. Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G, et al. A. Pentraxin 3 in acute respiratory distress syndrome: An early marker of severity. Crit Care Med 2008; 36(8): 2302-8.
71. Muller B, Peri G, Doni A, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001; 29: 1404-1407.
72. Jaillon S, Peri G, Delneste Y, Fremaux I, Doni A, Moalli F, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007; 204(4): 793-804.
73. Dodds DC, Omeis IA, Cushman SJ, Helms JA, Perin MS. Neuronal pentraxin receptor, a novel putative integral membrane pentraxin that interacts withneuronal pentraxin 1 and 2 and taipoxin-associated calcium-binding protein 49. J Biol Chem 1997; 272(34): 21488-94.
74. Zoheir N, Lappin DF, Nile CJ. Acetylcholine and the alpha 7 nicotinic receptor: A potential therapeutic target for the treatment of periodontal disease? Inflamm Res 2012; 61(9): 915-26.
75. Abad MA, Enguita M, DeGregorio-Rocasolano N, Ferrer I. Trullas Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid-beta and is over expressed in dystrophic neurites in Alzheimer's brain. J Neurosci 2006; 26(49): 12735.
76. Enguita M, DeGregorio-Rocasolano N, Abad A, Trullas R. Glycogen synthase kinase 3 activity mediates neuronal pentraxin 3 activity mediates neuronal pentraxin 1 expression and cell death induced by potassium deprivation in cerebellar granule cells. Mol Pharmacol 2005; 67(4): 1237-46.
77. Meechan JG, Rawlins MD. The effects of two different dental local anesthetic solutions onplasma potassium levels during third molar surgery. OOO 1988; 669 (6): 650-653.
78. Hossain MA, Russell JC, O'Brien R. J Leterra Neuronal pentraxin 1: A noval mediator of hypoxic-ischemic injury in neonatal brain J Neurosci 2004; 24(17): 4187-96.
79. Crocker A, España RA, Papadopoulou M, Saper CB, Faraco J, Sakurai T, Honda M, Mignot E, Scammell TE. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005; 65(8): 1184-8.
80. Yin GN, Lee HW, Cho JY, Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res 2009; 1265: 158-70.
81. Kamer AR, Craig RG, Dasanayake AP, Brys M, Glodzik-Sobanska L, de Leon MJ. Inflammation and Alzheimer's disease: Possible role of periodontal disease. Alzheimers Dement 2008; 4(4): 242-50.